The KYNA/KYN ratio was significantly lower in the EM group (p < 0.05), and significantly higher in the post-intervention RM group (p < 0.05) and not statistically different from the RC group (p > 0.05) (Figure 6D), suggesting that epilepsy leads to the impairment of neuroprotective metabolic pathways, and that the inhibition of KMO can effectively reverse this pathological change. Here, KMO is linked to epilepsy.